Company / Profit Margin
Seres Therapeutics, Inc. Profit Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-45.3%
FY2023
5-year range
-350.0% / -45.3%
FY2019-FY2023
Trend
+83.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has fluctuated over the past 8 years, ranging from -420.7% in FY2018 to -45.3% in FY2023.
Based on SEC 10-K filings.
-45.3% in FY2023 with a 5-year CAGR of +375.5%.
Improved from -203.7% to -45.3% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +304.8pp
- 5-Year Change
- +375.5pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, profit margin increased 83.1% year-over-year.
- Lowest profit margin in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2023 | -45.3% | +83.1% |
| FY2022 | -268.3% | -31.7% |
| FY2021 | -203.7% | +41.8% |
| FY2020 | -350.0% | -25.7% |
| FY2019 | -278.4% | +33.8% |
| FY2018 | -420.7% | -67.2% |
| FY2017 | -251.7% | -227.8% |
| FY2016 | -76.8% | - |
| FY2015 | - | - |
As of FY2023 · SEC Form 10-K · Last checked Jun 24, 2026